Maquet slapped with Class I recall; Elixir kicks off FDA-targeted stent trial;

Medical Device News

 @FierceMedDev: FDA warns of criminals hocking stolen Covidien stapler reloads. More | Follow @FierceMedDev

 @MarkHFierce: Biotronik won FDA approval for ICD/CRT-D devices, keeping it in the global race to unveil new products in the space. Story | Follow @MarkHFierce

 @DamianFierce: Stan Musial rises from the grave and takes a job at a specialty pharma outfit. Amazing, really. Release | Follow @DamianFierce

> Elixir Medical gained FDA approval to begin enrolling patients in EXCELLA III, a multisite U.S. trial to test the DESyne Nx Novolimus Eluting Coronary Stent System. The results will fuel a PMA application. Release

> The FDA has affixed its most-serious Class I tag to Maquet's March recall of SERVO-i Ventilator battery modules. More

> Medical device companies are increasingly responding to cost concerns expressed by insurers, with less of a focus on doctors and patients, a new report commissioned by MassMEDIC concludes. Story

> Navidea Biopharmaceuticals ($NAVB) took a $7 million loss last quarter as the company ramps up commercialization of its Lymphoseek diagnostic aid. Results

> Insulin pump maker Insulet ($PODD) enjoyed a 14% stock surge on Tuesday after reporting $57.4 million in revenue during the 2013 first quarter, a 20% spike that also comes with narrowed net losses. Story

> Cancer Genetics ($CGIX) has partnered with Nikon Instruments to distribute oncology-focused diagnostics technologies in Italy. Item

> A team of researchers from the University of Southern California and elsewhere are developing a microchip implant to help restore memories in patients with impaired brains, with human trials expected within two years. Story

Biotech News

 @FierceBiotech: Nimbus Discovery announced agreement with Shire focused on small molecule treatments for rare genetic diseases. Release | Follow @FierceBiotech

 @JohnCFierce: Painful to watch Vivus ($VVUS) scratching out sales for its weight drug. It's not built to market a drug like that. More | Follow @JohnCFierce

 @RyanMFierce: Pfizer opts to keep running Accelrys software in its labs. Article | Follow @RyanMFierce

> Genomics, Biotechnology's Oldest Next Big Thing. Industry Voices

> Startup biotech charges into PhII with $23M bankroll for rare disease drugs. Article

> Takeda beefs up new vaccines arm with $250M bolt-on buyout of Inviragen. News

Pharma News

 @FiercePharma: India's own drugmakers are turned off their home market by gov't policy. For them, it's price caps. More | Follow @FiercePharma

 @EricPFierce: Rapidly growing Sagent takes control of FDA approved China plant that it is ready to produce products. Article | Follow @EricPFierce

> U.S. Judge lashes out at FDA over its Plan B maneuver. Story

> The pharma spin-offs have just begun, bankers figure. News

> GSK taps "independent" experts to control trial-data access. More

Drug Delivery News

 @MichaelGFierce: Frederick National Lab leads nanotech boom with cancer drug delivery. Report | Follow @MichaelGFierce

> "Buckyball" capsule lets researchers steer drugs to target. Article

> Math model could choose most effective drug delivery nanoparticle. Story

> Langer's Kala touts positive results for topical wet AMD treatment. Report

> "Smart" insulin nanoparticle controls blood sugar levels for up to 10 days. More

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.